Source: AIDS  |  Posted 8 years ago

Combining doxorubicin with cisplatin produces a significantly higher response rate in patients with endometrial adenocarcinoma than does doxorubicin monotherapy, research from Switzerland indicates.

Investigators from Hopital Cantonal Universitaire in Geneva report a modest survival benefit is achieved, especially in patients who have a good performance status. Median overall survival was nine months in combination therapy patients and seven months in monotherapy patients. They add that toxicity is higher but acceptable with combination therapy.

A total of 177 patients with histologically proven advanced and/or recurrent endometrial adenocarcinoma were enrolled. Median follow-up was 7.1 years. Participants were chemotherapy na